Spectral AI Beats on Loss Per Share but Revenue Misses by Nearly Half
MDAI is trading near its 52-week low of $1.18 (12% above the low).
Summary
Spectral AI posted a Q3 adjusted loss of 11 cents a share, better than the 13-cent loss two analysts expected, but revenue fell 24.7% to $2.86 million against a $5.33 million consensus — a miss of roughly 46%. The company lost $3.66 million in the quarter. The revenue shortfall is the real story for a micro-cap that burned cash through Q2 and carries a material weakness in financial controls, even as it prepares to launch its FDA-cleared DeepView System. The lone analyst rating is a buy with a $5.13 median price target, but that target sits far above the $1.32 stock and the estimate trend has been drifting lower. This follows the September 8-K investor presentation that framed the $150M BARDA contract and $14.0M cash position as the core of the story — the weak top line puts more weight on that contract converting to revenue.
At the time of this announcement, MDAI was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.6M. The 52-week trading range was $1.18 to $2.97. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.